Shaman Pharmaceuticals Inc., which develops drugs fromtropical plants with a history of folk use, has raised $7.6 millionin a second round of venture financing. Investors includeTechnology Funding Inc., Delphi BioVentures, Salomon Brothers,Sequoia Capital, Walden Group, Capital Health VenturePartners, Pathfinder Venture Capital, Kinship Partners, DavidHamilton Smith Investments, and Odyssey Fund.
The San Carlos, Calif., company previously raised $5.5 millionfrom Technology Funding, Delphi, Elf Technology, Calvert SocialVenture Fund and individual investors. Inverni della Beffa ofMilan, Italy, with which Shaman has a manufacturing alliance,also has an undisclosed equity investment in Shaman.
The company's lead product, SP-303, entered Phase I trials inOctober to treat respiratory syncytial virus.
(c) 1997 American Health Consultants. All rights reserved.